Media Center

Archives: Press Release

Entasis Therapeutics Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program

WALTHAM, Mass. — October 12, 2017 — Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced that it has received a CARB-X award to progress its pre-clinical penicillin-binding protein (PBP) inhibitor program from lead optimization through Phase 1 clinical trials. The award commits initial funding up to […]

Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials

WALTHAM, Mass. — October 9, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced the results of its four-part, Phase 1 study in healthy subjects of ETX2514, a clinical-stage compound under development in combination with sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections. The results were […]

Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017

100917_Entasis IDWeek ETX2514 Abstract PR FINALFDA grants Qualified Infectious Disease Product (QIDP) and Fast Track designation to ETX2514SUL, the combination of ETX2514 with sulbactam WALTHAM, Mass. — September 28, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced the presentation of data on ETX2514 at IDWeek 2017, […]

Entasis Announces $31.9 Million Extension of Series B Financing to Advance Anti-infective Therapeutic Portfolio

  Series B-1 Funding will Support the Company’s Programs to Treat Multidrug-Resistant Gram-negative Infections WALTHAM, Mass. — September 5, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced the closing of an upsized $31.9 million Series B-1 extension financing to advance its pipeline of clinical and preclinical […]

Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to Develop a New Treatment for Drug-Resistant Gonorrhea

First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea July 6, 2017 – Boston/Geneva – Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between […]

Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas

Report in Nature Microbiology Describes Entasis’ Rational Design of a Next-generation Beta-Lactamase Inhibitor with an Expanded Spectrum of Beta-Lactamase Activity WALTHAM, Mass. – June 30, 2017 – Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, published a report in Nature Microbiology (DOI: 10.1038/nmicrobiol.2017.104) in which Entasis scientists describe the rational design and […]

Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum Βeta-lactamase Inhibitor, at ASM Microbe 2017

Presentations Also Highlight the Activity of ETX2514 Combinations against Acinetobacter and Pseudomonas   WALTHAM, Mass. — June 7, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, delivered multiple presentations at the American Society of Microbiology (ASM) Microbe 2017 Conference, June 1-5 in New Orleans, Louisiana. The presentations featured […]

Entasis Therapeutics to Present at Upcoming June 2017 Investor Conferences

WALTHAM, Mass. — May 31, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that CEO, Manos Perros will present at two upcoming investor conferences in June, the Jefferies Global Healthcare Conference taking place in New York, NY on June 6 to 9, and the JMP Securities […]

Entasis Therapeutics to Present Data on ETX2514 and Entasis’ Third Drug Candidate, ETX0282, at ASM Microbe 2017

WALTHAM, Mass. — May 22, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced multiple presentations at the American Society of Microbiology (ASM) Microbe 2017 Conference, taking place June 1-5 in New Orleans, LA. Presentations will include data on Entasis’ lead program, ETX2514, as well as an […]

Entasis Therapeutics to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WALTHAM, Mass. — April 21, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced two oral presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April  22 – 25 in Vienna, Austria. Both presentations will highlight the preclinical profile […]